Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Eur J Ophthalmol ; 32(3): 1370-1374, 2022 May.
Article in English | MEDLINE | ID: covidwho-1868965

ABSTRACT

INTRODUCTION: To report the posterior corneal changes after Bowman Layer Transplant for keratoconus in a tertiary hospital in the UK. METHODS: 5 eyes of 5 patients receiving Bowman Layer Transplant for advanced keratoconus in Royal Gwent Hospital (Newport, UK) were included. Pre and postoperative posterior corneal astigmatism, posterior Kmean, and back surface elevation were analysed. RESULTS: No significant changes were seen in the posterior corneal astigmatism, posterior Kmean, or back surface elevation between the pre- and postoperative period. CONCLUSION: This results would support the idea that the corneal changes seen after Bowman Layer Transplant are mainly in the anterior corneal surface.


Subject(s)
Astigmatism , Keratoconus , Cornea , Corneal Topography/methods , Humans , Keratoconus/surgery , Refraction, Ocular , Visual Acuity
2.
Cornea ; 41(5): 669-672, 2022 May 01.
Article in English | MEDLINE | ID: covidwho-1778964

ABSTRACT

PURPOSE: The purpose of this study was to report 5 cases of acute corneal graft rejection after COVID-19 vaccination and perform a review of the literature. METHODS: This was a case series and review of literature dated on the October 10, 2021. RESULTS: We describe 5 cases-2 patients with Descemet stripping automated endothelial keratoplasty (for Fuchs endothelial dystrophy) who presented with acute corneal graft rejection after their first dose of mRNA (BNT162) vaccine. The other 3 patients who had penetrating keratoplasty performed more than 10 years ago for keratoconus presented with acute graft rejection-2 patients after their second dose of adenovirus vector (AZD1222) vaccine and 1 patient after first dose of mRNA (BNT162) vaccine. Three patients were not using any topical steroid treatment at the time of diagnosis of graft rejection. The mean duration between vaccination and onset of symptoms was 16.86 ± 6.96 days for the mRNA vaccine and 17 ± 11.89 days for the adenovirus vector vaccine. CONCLUSIONS: Corneal graft rejection has recently been reported after COVID-19 vaccination. Patients with keratoplasty need to be advised regarding the risk of corneal graft rejection and warning symptoms of rejection after COVID-19 vaccination. Seeking early referral to the emergency department and increasing topical steroids pre-COVID-19 and post-COVID-19 vaccination may reduce the risk of rejection.


Subject(s)
COVID-19 , Corneal Diseases , Descemet Stripping Endothelial Keratoplasty , Keratoconus , COVID-19 Vaccines/adverse effects , ChAdOx1 nCoV-19 , Corneal Diseases/surgery , Graft Rejection/diagnosis , Humans , Keratoconus/surgery , Keratoplasty, Penetrating/adverse effects , Retrospective Studies , Vaccination/adverse effects , Vaccines, Synthetic , mRNA Vaccines
3.
Cornea ; 41(2): 257-259, 2022 Feb 01.
Article in English | MEDLINE | ID: covidwho-1483573

ABSTRACT

PURPOSE: The purpose of this article was to report a case of full-thickness corneal transplant rejection 3 days after immunization with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Moderna mRNA-1273 vaccine. METHODS: Case Report. RESULTS: A 51-year-old man with a history of keratoconus and penetrating keratoplasty underwent repeat penetrating keratoplasty for graft failure. The patient had an uncomplicated intraoperative and postoperative course with improved vision and a healthy graft. The patient received the SARS-CoV-2 Moderna vaccine on postoperative week 3, and within 3 days, the patient began developing eye pain, photophobia, and blurred vision. The patient was found to have graft rejection with corneal edema and endothelial keratic precipitates. The rejection did not improve despite a trial of increased topical steroids and ultimately evolved into graft failure. CONCLUSIONS: To the best of our knowledge, this case of full-thickness graft rejection after the Moderna SARS-CoV-2 mRNA vaccination is the first to be reported worldwide. The temporal relationship between vaccination and subsequent rejection is highly suggestive of causation due to the short interval (3 days) between vaccination and rejection and the lack of other inciting factors in an otherwise healthy graft. Patients with corneal transplants who plan to take the COVID-19 vaccinations should be counseled on symptoms and closely monitored, and an individualized plan should be made in discussion with the ophthalmologist.


Subject(s)
2019-nCoV Vaccine mRNA-1273/adverse effects , Graft Rejection/etiology , Keratoplasty, Penetrating , Vaccination/adverse effects , Acute Disease , COVID-19/prevention & control , Graft Rejection/diagnosis , Graft Rejection/surgery , Humans , Keratoconus/surgery , Male , Middle Aged , Reoperation , SARS-CoV-2 , Visual Acuity
4.
Cornea ; 40(1): 123-124, 2021 Jan.
Article in English | MEDLINE | ID: covidwho-998523

ABSTRACT

PURPOSE: To report a case of acute corneal endothelial graft rejection with the concurrent onset of coronavirus disease 2019 (COVID-19) symptoms. METHODS: Case report. RESULTS: A 31-year-old African American woman with a history of asthma, sleep apnea, obesity (body mass index of 40), and bilateral keratoconus was noted to have acute corneal endothelial graft rejection 3 months after uncomplicated penetrating keratoplasty of the left eye. The patient developed dysgeusia and subjective fever on the same day as ocular discomfort, and she was subsequently diagnosed with COVID-19 with only these 2 classic symptoms of the viral infection. CONCLUSIONS: Severe acute respiratory syndrome coronavirus 2 is known to cause conjunctivitis and has demonstrated transmissibility through ocular secretions. Acute immune and inflammatory dysregulations have been seen in cases of COVID-19 through various mechanisms. COVID-19 infection may potentially compromise ocular immune privilege contributing to acute corneal graft rejection.


Subject(s)
COVID-19/diagnosis , Endothelium, Corneal/pathology , Graft Rejection/diagnosis , Keratoconus/surgery , Keratoplasty, Penetrating , SARS-CoV-2 , Acute Disease , Adult , COVID-19/etiology , COVID-19 Testing , Dysgeusia/diagnosis , Female , Graft Rejection/etiology , Humans , Polymerase Chain Reaction , Reoperation , Visual Acuity/physiology
5.
Indian J Ophthalmol ; 68(11): 2471-2474, 2020 Nov.
Article in English | MEDLINE | ID: covidwho-895453

ABSTRACT

A donor corneo-scleral button was dissected into four parts using a simple manual technique. The anterior corneal lamellae was stripped from the Descemet's Membrane (DM) and Deep Anterior Lamellar Keratoplasty (DALK) was performed in a patient with advanced keratoconus after removing the recipient's stroma using the big bubble technique. Descemet's Membrane Endothelial Keratoplasty (DMEK) was done with the stripped donor DM in a patient with Fuch's endothelial dystroph (FECD). The cadaveric limbal stem cells from the tissue were used for simple limbal epithelial transplantation (SLET) in a Steven- Johnson Syndrome (SJS) with localized limbal stem deficiency and symblepharon. The sclera was used to revise a leaking hypotonus bleb in an advanced single-eyed glaucoma patient. No intraoperative or postoperative complications were observed. At 1 year, all the 4 cases retained healthy transplanted tissues with good visual outcomes. Shortage of donor eyes is a global problem and with the present COVID-19 scenario the situation is bound to worsen. The advent of customized component corneal transplantation using simple cost-effective techniques will be the future trend in the years to come.


Subject(s)
Betacoronavirus , Corneal Transplantation , Coronavirus Infections/epidemiology , Fuchs' Endothelial Dystrophy/surgery , Glaucoma/surgery , Keratoconus/surgery , Pneumonia, Viral/epidemiology , Sclera/transplantation , Stevens-Johnson Syndrome/surgery , Tissue Donors , Adolescent , Aged , COVID-19 , Conjunctival Diseases/surgery , Descemet Stripping Endothelial Keratoplasty , Female , Filtering Surgery , Humans , Male , Middle Aged , Pandemics , SARS-CoV-2 , Stem Cell Transplantation , Transplant Recipients
SELECTION OF CITATIONS
SEARCH DETAIL